Ogawa M, Ariyoshi Y
Aichi Cancer Center Hospital.
Gan To Kagaku Ryoho. 1993 Jan;20(1):27-33.
Idarubicin showed the superior activity against Acute Non-Lymphocytic Leukemia (ANLL) in the prospective randomized trials comparing to daunorubicin and it is judged that the analog will become the first choice in the treatment on ANLL. Anthracyclines including SM-5887, KRN-8602, ME-2303 under studies in Japan have shown comparable or superior antitumor activities and lower cardiac toxicities compared to doxorubicin in preclinical studies and therefore the results obtained in clinical trials are expected. Phase II trials of anthrapyrazoles which is an analog of mitoxantrone are in progress. Among three compounds entered it is of note that CI-941 has demonstrated an excellent activity against advanced breast cancer.
在比较伊达比星与柔红霉素的前瞻性随机试验中，伊达比星对急性非淋巴细胞白血病（ANLL）显示出更强的活性，并且据判断该类似物将成为ANLL治疗的首选。在日本正在研究的包括SM - 5887、KRN - 8602、ME - 2303在内的蒽环类药物，在临床前研究中已显示出与多柔比星相当或更强的抗肿瘤活性以及更低的心脏毒性，因此期待在临床试验中获得相关结果。作为米托蒽醌类似物的蒽吡唑类的II期试验正在进行。在进入试验的三种化合物中，值得注意的是CI - 941已显示出对晚期乳腺癌具有优异的活性。
